Fredrik Olsson (Baulos Capital) has informed the NeuroVive board of Baulos Capital's intention to subscribe for shares in NeuroVive's rights issue with a subscription period between April 18 – May 2, 2016. The commitment means a subscription of at least 75,000 units to the rights issue subscription price of 42 SEK, corresponding to 3.15 MSEK.
Baulos Capital has also agreed to sell off unexercised warrants outside of the stock market to selected international investors.
Members of NeuroVive's management team, including the company's CEO Erik Kinnman and COO Jan Nilsson, have expressed a desire to subscribe for units in the rights issue.
NeuroVive Pharmaceutical AB (publ) is a pioneer in mitochondrial medicine and a company committed to the discovery and development of highly targeted candidates that preserve mitochondrial integrity and function in areas of significant therapeutic need. NeuroVive’s business approach is driven by value-adding partnerships with mitochondrial research institutions and commercial partners across the globe. NeuroVive’s portfolio consists of two clinical projects in acute kidney injury (AKI) and traumatic brain injury (TBI) with candidates in clinical and preclinical development and two drug discovery platforms. The NeuroSTAT® product has orphan drug status in Europe and in the US for treatment of moderate to severe traumatic brain injury and is currently being evaluated in a study, CHIC. Ciclosporin (CicloMulsion®) is being evaluated in an on-going study, CiPRICS, in acute kidney injury during major surgery. NeuroVive’s shares are listed on Nasdaq, Stockholm, Sweden.
For investor relations and media questions, please contact:
Christine Tadgell, NeuroVive, Tel: +46 (0)46 275 62 21 or email@example.com
NeuroVive Pharmaceutical AB (publ) is required to publish the information in this news release under The Swedish Securities Market Act. The information was submitted for publication on the 18 April 2016, at 8.30 CET.